Pharmaceutical

EC approves BMS’ Opdivo and Yervoy combo for HCC

The EC has approved BMS Opdivo in combination with Yervoy as a first-line treatment for adults with unresectable or advanced HCC.

Mar 11, 2025 - 06:00
EC approves BMS’ Opdivo and Yervoy combo for HCC
The EC has approved BMS Opdivo in combination with Yervoy as a first-line treatment for adults with unresectable or advanced HCC.
Read the original article

Tags:

Previous Article

Alliance Pharma agrees to £362m acquisition by DBAY

Next Article

Sun Pharma agrees to acquire Checkpoint Therapeutics

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Former surgeon general Jerome Adams tries to outrun the shadow of the president he served

STAT+: Former surgeon general Jerome Adams tries to out...

Mar 26, 2023

STAT+: Colombia set to issue a compulsory license for an HIV medicine sold by GSK’s ViiV

STAT+: Colombia set to issue a compulsory license for a...

Oct 4, 2023

Supreme Court backs Sanofi in high-profile cholesterol drug suit with Amgen

Supreme Court backs Sanofi in high-profile cholesterol ...

May 20, 2023